Brief: Paion AG Reports Developments On Commercial Activities In Europe

PAION AG

24/06/2022 08:10

June 24 (Reuters) - PAION AG  PA8G.DE :
    * COMPANY REPORTED THAT PRICING AND REIMBURSEMENT LEVELS FOR
REMIMAZOLAM HAVE BEEN TRACKING ABOVE INITIAL TARGETS, WITH
AVERAGE NET SELLING PRICE FOR REMIMAZOLAM AROUND EUR 19 PER 20
MG, WHICH IS AT HIGH END OF PAION'S PRICING EXPECTATIONS
    * EXPECTS TO SEE AN INCREASED AND STEADIER UPTAKE OF ITS
PRODUCTS
IN UK GOING FORWARD
    * EXPECTS STRONG SYNERGIES AND HIGHLY EFFICIENT DEPLOYMENT
OF
SALES FORCE DUE TO MARKETING OF SEVERAL PRODUCTS
    * CURRENTLY ONLY ANGIOTENSIN II IS AVAILABLE TO HOSPITALS
AND
PAION EXPECTS TO SUCCESSFULLY CONCLUDE REIMBURSEMENT DISCUSSIONS
AND CONTRACTS WITH INSURERS IN JULY 2022

Source text for Eikon:  ID:nEQ1Fv4TXa 
Further company coverage:  PA8G.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))